

## ORIGINAL ARTICLE

# Long-term sexual outcomes after holmium laser enucleation of the prostate: which patients could benefit the most?

P Capogrosso<sup>1,2</sup>, E Ventimiglia<sup>2</sup>, M Ferrari<sup>2</sup>, A Serino<sup>2</sup>, L Boeri<sup>2</sup>, U Capitanio<sup>2</sup>, A Briganti<sup>2,3</sup>, R Damiano<sup>3</sup>, F Montorsi<sup>1,2</sup> and A Salonia<sup>1,2</sup>

Assess rate and predictors of erectile function (EF) outcomes at long-term follow-up (FU) after holmium laser enucleation of the prostate (HoLEP). Cross-sectional analyses were performed on 135 patients with a mean FU of 12 years post HoLEP. Patients completed both a baseline and a FU International Index of Erectile Function (IIEF)-EF domain and the International Prostatic Symptoms Score (IPSS). Postoperative EF outcomes, including rate and predictors of EF improvement considering minimal clinically important differences (MCIDs) criteria, were assessed. Logistic regression models tested the association between predictors and EF. At a mean (median) FU of 152.1 (163) months, patients showed a significant decrease in the IIEF-EF score ( $P < 0.01$ ) and significant IPSS improvement ( $P < 0.01$ ). Overall, 50 (37%) patients worsened by at least one IIEF-EF category. Conversely, 23 (17%) patients reported an improvement in postoperative IIEF-EF score; 75 (55.6%) and 10 (7.4%) patients maintained and eventually improved their IIEF-EF category, respectively. Patients reporting a decrease in the postoperative IIEF-EF score were significantly older ( $P = 0.03$ ) and showed a significantly longer mean FU ( $P < 0.01$ ) than those reporting postoperative improvements of IIEF-EF. Nine (6.7%) patients showed significant EF improvement according to MCIDs criteria. Both higher IPSS scores (odds ratio (OR): 1.12;  $P = 0.02$ ) and lower IIEF-EF (OR: 0.88;  $P < 0.01$ ) at baseline, emerged as independent predictors of postoperative EF improvement. HoLEP was associated with a decrease in EF and a persistent amelioration of BPH-related urinary symptoms at long-term FU. Almost one third of patients worsened by at least one IIEF-EF category. However, a clinically meaningful EF improvement was observed in roughly 7% of the individuals. Patients with more severe preoperative urinary symptoms and ED benefited more from HoLEP in terms of EF.

*International Journal of Impotence Research* (2016) **28**, 189–193; doi:10.1038/ijir.2016.29; published online 28 July 2016

## INTRODUCTION

Erectile dysfunction (ED) and benign prostatic hyperplasia-related lower urinary tract symptoms (LUTS/BPH) are highly prevalent and comorbid conditions in middle-aged and elderly men.<sup>1</sup> Data regarding the incidence of ED after surgery for LUTS/BPH has shown conflicting results.<sup>2–7</sup> Trans-urethral resection of the prostate (TURP) is still considered the gold standard for BPH surgery, and has been associated with a postoperative ED prevalence of 13%.<sup>8–11</sup> Holmium laser enucleation of the prostate (HoLEP) is an effective, prostate size-independent and safe surgical alternative for LUTS/BPH,<sup>12</sup> with functional results similar to TURP both in terms of relief of subjective symptoms and urodynamic outcomes.<sup>4,8,13,14</sup>

The literature suggests similar rates of postoperative ED in patients treated with HoLEP, TURP or open prostatectomy, although the majority of these studies do not rely on validated instruments to assess erectile function (EF) outcomes.<sup>4,5,13,15</sup> Conversely, using the International Index of Erectile Function (IIEF), Briganti *et al.*<sup>2</sup> showed a positive albeit not significant linear correlation between EF improvement and a concomitant postoperative LUTS amelioration in patients treated with either HoLEP or TURP.

We sought to assess (1) the rate of EF alteration at long-term follow-up (FU) after HoLEP using validated psychometric instruments, (2) clinically meaningful improvements in postoperative EF according to the minimal clinically important differences (MCIDs), defined as the smallest difference in the IIEF-EF domain score that

patients perceived as beneficial) criteria<sup>16</sup> and (3) potential clinical predictors associated with postoperative EF changes.

## MATERIALS AND METHODS

These cross-sectional analyses were based on a cohort of 636 consecutive sexually active, heterosexual, Caucasian-Europeans with LUTS/BPH submitted to HoLEP at a single academic hospital, between January 2001 and June 2011. All surgical procedures were performed by one fully trained surgeon, according to the surgical technique previously described in detail.<sup>13</sup> All subjects were preoperatively assessed with a thorough medical history; health-significant comorbidities were scored with the Charlson Comorbidity Index (CCI)<sup>17</sup> (categorized as 0 vs  $\geq 1$ ). We used the International Classification of Diseases, 9th revision, Clinical Modification (ICD-9-CM). Preoperative prostate volume was assessed via trans-rectal ultrasound evaluation.

Patients were stratified according to their educational status into a low-level educational group, which included patients with an elementary and/or secondary school education, and a high-level educational group, which consisted of men with a high school and/or university degree.

Moreover, all patients completed a baseline IIEF-EF domain<sup>18</sup> and International Prostate Symptom Score (IPSS).

From July to December 2012 all patients were re-assessed with a single out-patient clinic visit at a minimum FU of 12 months. Patients were invited to fill a IIEF and a IPSS targeting 4 week before the FU visit. All surveys were self-administered in a clinical setting. For the specific purposes of the study, all patients reporting to have used pro-erectile drugs in the last 4 weeks were excluded (125(19.6%)). Similarly patients with incomplete baseline data or refusing to complete the FU survey

<sup>1</sup>Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; <sup>2</sup>Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, University vita-Salute San Raffaele, Milan, Italy and <sup>3</sup>Research Doctorate Program in Urology, Magna Graecia University, Catanzaro, Italy. Correspondence: Professor A Salonia, Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, University vita-Salute San Raffaele, Via Olgettina 60, 20132 Milan, Italy. E-mail: salonia.andrea@hsr.it

Received 23 September 2015; revised 22 February 2016; accepted 8 May 2016; published online 28 July 2016

(367(57.7%)) and those who underwent a redo-surgery during FU (10 (1.5%)) were excluded from the study. Overall, a total of 135 patients with complete baseline and FU data were included in the final analysis.

To provide a frame of reference for objectively interpreting ED severity, we used the IIEF-EF domain classification as proposed by Cappelleri *et al.*<sup>19</sup> MCIDs were defined as 2, 5 and 7 for patients with mild, moderate and severe preoperative ED, respectively; patients with mild to moderate ED were included in the moderate category.<sup>16</sup>

Data collection followed the principles outlined in the Declaration of Helsinki; all patients signed an informed consent agreeing to supply their own anonymous information for this and future studies.

### Main outcome measures

The primary end point of the present study was to assess EF changes at long-term FU after HoLEP. Moreover, the rate of patients with clinically meaningful improvements in postoperative IIEF-EF according to the MCIDs criteria<sup>16</sup> was also assessed. A secondary endpoint was to identify the clinical predictors of long-term post-HoLEP EF improvement or deterioration in the same cohort of patients.

### Statistical analysis

Clinical and sociodemographic characteristics of the patients are presented as means (medians; s.d.) and ranges. Descriptive statistics were used to analyze rates of pre- vs postoperative changes in IIEF-EF and IPSS. Differences in means and proportions were tested with the paired Student's *t*-test, and the  $\chi^2$  test, respectively. Correlations were assessed using Spearman's or Pearson's method, whenever appropriate.

Univariable (UVA) and multivariable (MVA) linear and logistic regression models tested the association between predictors (for example, age, educational status, body mass index (BMI), CCI, preoperative IPSS and preoperative IIEF-EF, length of FU, prostate volume) and EF improvement or deterioration at long-term FU. Statistical analyses were performed using SPSS statistical software, v 20.0 (IBM Corp., Armonk, NY, USA). All tests were two sided, with a significance level set at 0.05.

## RESULTS

Table 1 lists the socio-demographic and clinical characteristics of the entire cohort of patients. Preoperative and FU psychometric values are detailed in Table 2. Similarly, Table 2 also reports pre- and postoperative rates of ED severity according to Cappelleri's classification criteria. At a mean FU of 152.1 months, patients showed a significant total IPSS improvement; a similar amelioration was observed for both storage and voiding symptoms (all  $P < 0.01$ ). A significant decrease in terms of mean IIEF-EF scores was observed at FU, with a mean delta of 3.9 ( $P < 0.01$ ). Fifty (37%) patients worsened by at least one IIEF-EF category. Conversely, 23 (17%) patients reported an improvement in postoperative IIEF-EF score. Overall, 75 (55.6%) patients maintained the same baseline IIEF-EF category, and 10 (7.4%) patients showed an improvement of at least one IIEF-EF category after surgery.

Age at survey was inversely correlated to IIEF-EF score at FU ( $\rho = -0.25$ ;  $P < 0.01$  (95% confidence interval (CI)  $-0.40, -0.086$ )); indeed patients reporting a decrease in IIEF-EF scores were significantly older (68.7 (6.9) vs 65.3 (6.5) years;  $P = 0.03$ ) and showed a significantly longer mean FU (165.8 (86.4) vs 85.7 (82.4) months;  $P < 0.01$ ) compared to those reporting a postoperative improvement of IIEF-EF.

Table 2 also details IIEF-EF domain score improvements according to MCIDs criteria; overall, 9 (6.7%) patients had a postoperative MCID improvement of IIEF-EF.

At UVA, younger age, lower prostate volume, a higher preoperative IPSS score, and a lower baseline IIEF-EF score were positively associated with EF improvement after surgery (all  $P \leq 0.03$ ) (Table 3). Similarly, at MVA, lower baseline IIEF-EF scores and higher baseline IPSS scores, emerged as independent predictors of EF improvement at survey (all,  $P \leq 0.03$ ), whereas all other variables failed to predict improvement (Table 3).

**Table 1.** Sociodemographic and clinical characteristics of the whole cohort of patients

No. of patients	135
<b>Age</b>	
Mean (median; s.d.)	68.1 (68; 6.8)
Range	50–85
<b>Follow-up (months)</b>	
Mean (median; s.d.)	152.1 (163; 90.5)
Range	12–168
$\geq 5$ -year follow-up (N (%))	104 (77)
$\geq 8$ -year follow-up (N (%))	82 (60.7)
$\geq 10$ -year follow-up (N (%))	78 (57.8)
<b>Prostate volume (ml)</b>	
Mean (median; s.d.)	54.7 (53; 24.3)
Range	20–124
<b>BMI (kg/m<sup>2</sup>)</b>	
Mean (median; s.d.)	26.1 (25.7; 4.3)
Range	20–56.8
<b>Educational status (N (%))</b>	
LL	15 (10.9)
HL	120 (89.1)
<b>CCI (N (%))</b>	
0	98 (72.4)
$\geq 1$	37 (27.6)
<b>Baseline IIEF-EF</b>	
Mean (median; s.d.)	23.12 (27; 8.8)
Range	0–30
<b>Baseline IPSS</b>	
Mean (median; s.d.)	15.9 (16; 8.6)
Range	5–32

Abbreviations: BMI, body mass index; HL, high-level educational level; IIEF-EF, International Index of Erectile Function-erectile function domain; IPSS, International Prostatic Symptom Score; LL, low-level educational level.

Table 3 also depicts UVA and MVA testing predictors of IIEF-EF deterioration. At UVA, both age and length of FU were positively associated with postoperative IIEF-EF deterioration; conversely, baseline IPSS was inversely associated with a decrease of IIEF-EF (Table 3). Likewise, MVA showed that baseline IPSS and length of FU emerged as independent predictors of IIEF-EF deterioration, whereas all other variables did not (Table 3).

## DISCUSSION

We tested long-term EF changes in a homogenous cohort of Caucasian-European men submitted to HoLEP for LUTS/BPH with a high-volume, fully trained surgeon. We found that long-term mean IIEF-EF scores were reduced after HoLEP, with up to 37% of patients reporting a worsening of their EF. Length of FU emerged as an independent predictor of this deterioration. Conversely, 17% of patients reported a long-term EF improvement, with nearly 7% of patients showing a clinically meaningful improvement of postoperative IIEF-EF. Patients with a significant improvement of IIEF-EF after HoLEP had a mean FU of almost 7 years. Of clinical importance, the higher the severity of baseline LUTS and ED, the greater the long-term postoperative IIEF-EF improvement.

Our interest was fueled by the existing controversies in terms of EF after surgery for LUTS/BPH.<sup>9–11,20–22</sup> TURP is still considered the gold standard for the treatment of symptomatic BPH for prostates that do not exceed certain volumes.<sup>8</sup> In this context, the multicenter American Urological Association Cooperative Study,

**Table 2.** Preoperative and postoperative urinary symptoms and erectile function evaluation

	Preoperative assessment	Postoperative assessment	P-value <sup>a</sup> (95% CI)	Postoperative MCIDs improvements	
				Yes (N (%))	No (N (%))
<i>IPSS</i>					
Mean (median; s.d.)	15.9 (16; 8.6)	5.4 (4; 5.4)	< 0.01 (8.8–12.1)		
Range	0–32	0–26			
<i>Storage symptoms</i>					
Mean (median; s.d.)	8.9 (8; 7.6)	3.3 (2; 3.5)	< 0.01 (4.2–7)		
Range	0–15	0–15			
<i>Voiding symptoms</i>					
Mean (median; s.d.)	10.6 (12; 5.4)	2.7 (1; 3.8)	< 0.01 (6.7–9)		
Range	0–20	0–18			
<i>IIEF-EF score</i>					
Mean (median; s.d.)	23.1 (27; 8.8)	19.2 (23; 10.6)	< 0.01 (2.4–5.4)		
Range	0–30	0–30			
<i>ED severity (N (%))</i>					
No ED	83 (61.5)	57 (42.2)	< 0.01 ( $\chi^2$ : 9.3) (6.9, 31.1)	—	—
Mild ED	12 (8.9)	21 (15.6)	0.14 ( $\chi^2$ : 2.2) (–1.7, 15.1)	1 (0.7)	11 (8.6)
Mild-to-moderate ED	16 (11.9)	14 (10.4)	0.84 ( $\chi^2$ : 0.0) (–6.6, 9.6)	1 (0.7)	15 (11.1)
Moderate ED	8 (5.9)	7 (5.2)	0.99 ( $\chi^2$ : 0.0) (–5.5, 6.9)	2 (1.5)	6 (4.4)
Severe ED	16 (11.9)	36 (26.7)	< 0.01 ( $\chi^2$ : 8.6) (4.9, 24.5)	5 (3.7)	11 (8.1)

Abbreviations: CI, confidence interval; ED, erectile dysfunction; IPSS, International Prostatic Symptom Score; IIEF-EF, International Index of Erectile Function-Erectile Function domain; MCIDs, minimal clinically important differences. <sup>a</sup>ED severity was categorized according to the classification suggested by Cappelleri *et al.*<sup>26</sup> \*P-value according to two-tailed independent t-test or the Mann–Whitney U-test, and the  $\chi^2$  tests, as indicated

**Table 3.** Univariable (UVA) and multivariable (MVA) logistic regression models predicting either postoperative IIEF-EF improvement or deterioration

	IIEF-EF improvement		IIEF-EF deterioration	
	UVA	MVA	UVA	MVA
	OR; P-value	OR; P-value	OR; P-value	OR; P-value
Age	0.92; 0.03	0.96; 0.40	1.07; 0.03	1.03; 0.23
BMI	1.08; 0.15	0.95; 0.64	0.92; 0.15	1.07; 0.86
CCI (0 vs $\geq 1$ )	1.42; 0.50	2.40; 0.25	0.50; 0.70	0.33; 0.18
Educational status (LL vs HL)	1.77; 0.49	2.7; 1.00	0.5; 0.5	1.25; 0.72
Length of FU	—	—	1.01; < 0.01	1.01; 0.03
Baseline IIEF-EF	0.95; 0.03	0.88; < 0.01	—	—
Baseline IPSS	1.08; < 0.01	1.12; < 0.01	0.92; < 0.01	0.91; < 0.01
Prostate volume	0.96; < 0.01	0.13; 0.98	1.03; < 0.01	1.02; 0.10

Abbreviations: BMI, body mass index; CCI, Charlson Comorbidity Index; FU, follow-up; HL, high-level educational level; IIEF-EF, International Index of Erectile Function-Erectile Function domain; IPSS, International Prostatic Symptom Score; LL, low-level educational level; MVA, multivariable; OR, odds ratio; UVA, univariable.

based on data of 1000 men treated with TURP showed a postoperative ED rate of 13%.<sup>23</sup> A review of 29 RCTs comparing TURP with less invasive approaches reported a 6.5% mean rate of post-TURP ED, but this data was not based on standardized questionnaires.<sup>24</sup> Conversely, Leleifeld *et al.*<sup>9</sup> did not report changes of sexual functioning in up to 84% of 670 patients at 9 months after either TURP, finasteride treatment, or watchful waiting. More recently, Choi *et al.*<sup>25</sup> retrospectively evaluated IIEF-EF data from 108 patients treated with TURP and found no statistically significant decrease in terms of post- vs preoperative EF, with an IIEF-EF improvement in 14% of the patients. Dealing with theoretically less invasive methods, for instance Guo and Jin<sup>26</sup> reported that patients with prostate volumes  $\geq 70$  ml had a

worsening of the IIEF-5 score at 12 and 24 months after photoselective vaporization of the prostate (PVP), whereas Bruyere *et al.*<sup>3</sup> reported that post-PVP sexual function was unchanged.

The results on sexual function outcomes assessed after HoLEP are not different from other BPH surgery series.<sup>2–5,15,20,27–29</sup> In a prospective randomized trial with almost 7 years of FU, Gilling *et al.*<sup>4</sup> reported that there was no significant difference in IIEF scores between patients submitted to TURP or HoLEP, although the analyses lacked a preoperative EF assessment. Similarly, Kuntz *et al.*<sup>15</sup> found no differences in a cohort of 100 patients randomized to either TURP or HoLEP at a 12 months FU, with 11.2% and 10.5% of patients reporting decreases in potency after HoLEP and TURP, respectively.

To the best of our knowledge, we report for the first time real-life post-HoLEP long-term EF outcome data. One strength of this study is that the data originated from a single institute survey with a relatively large cohort of homogeneous, same-race patients for whom all surgical procedures and psychometric evaluations were performed using a consistent method. The major findings of the present study are that (1) mean IIEF-EF domain scores significantly decreased several months after HoLEP, although 63% of patients did not show a worsening of ED severity according to Cappelleri's categories; (2) however, an improvement of EF was observed in 17% of patients with a mean FU of 7 years; (3) finally mean IPSS scores revealed no LUTS symptoms even after such a long FU.

From a naturalistic perspective, a deterioration of erectile functioning could be at least partially expected so long after surgery. In this context, we observed that patients with a worsened IIEF-EF were significantly older and had a longer mean FU. Conversely, such a significantly consistent lack of long-term storage/voiding symptoms clearly emerges as a clinical success, a finding which should be carefully considered in daily clinical practice.

As a further major finding, baseline severity of LUTS and ED emerged as independent predictors of long-term postoperative EF improvement. As a whole, these findings support the concept of potential sexual function improvements as the result of a satisfactory BPH/LUTS treatment. In this regard, a number of studies support a common ageing-related incidence of ED and LUTS/BPH.<sup>30,31</sup> Recently Seftel *et al.* reviewed data from 23 epidemiologic studies correlating BPH/LUTS and ED, showing that one third of men  $\geq 50$  years complained of concomitant ED and LUTS/BPH.<sup>30</sup> Therefore, although we certainly admit that a 12-year FU could not represent a correct time frame to assess post-operative EF, we could argue that a IIEF-EF score improvement even after such a long postoperative time frame may become even more clinically relevant.

MCIDs criteria were applied for the first time to identify patients who actually perceived a beneficial EF improvement.<sup>16</sup> In this context, almost 7% of patients had a clinically meaningful EF improvement after surgery. A potential improvement in EF after surgery has been previously reported in literature;<sup>5,27–29</sup> in a 6-month FU survey with a non-validated questionnaire which investigated libido, potency and sexual satisfaction, Jeong *et al.*<sup>5</sup> reported a significant improvement in the number of early morning erections, a finding which the authors attributed to the concomitant amelioration of sleep quality due to the reduction of nocturia. Similarly, Meng *et al.*<sup>27</sup> reported that HoLEP did improve the ability to have early morning erections in patients treated for LUTS/BPH. Moreover, in a cohort of 60 patients evaluated with the Male Sexual Health Questionnaire (MSHQ) 6 months after HoLEP, a significant improvement in sexual satisfaction was correlated with the improvement of LUTS after surgery,<sup>28</sup> thus corroborating previous findings showing a postoperative IIEF-EF improvement, albeit non significant, with a positive linear correlation between the improvement of IPSS and QoL scores and EF findings.<sup>2</sup> We examined baseline clinical variables potentially associated with an EF improvement; in the current series, the more severe the baseline LUTS, the more significant the increase in postoperative IIEF-EF domain scores. Even more clinically relevant, patients with the lowest baseline IIEF-EF scores achieved the highest scores postoperatively. The practical consequence of these results in the real-life setting would be that patients with the worst baseline clinical characteristics (that is, severe LUTS/BPH, and severe ED) would likely benefit most from HoLEP in terms of both LUTS resolution and EF improvement.

Our study is not devoid of limitations. First, although the study provides absolutely original results in showing that the severity of preoperative ED is significantly associated with long-term EF improvement in men undergoing HoLEP, the lack of dedicated prospective functional time-to-time assessment throughout the

postoperative period could limit the significance of reported data. Similarly, although data collection was done in an adequate setting, it is not possible to completely eliminate the possibility that the authors' expectations could have, in some way, influenced patient reports. Third, the number of patients included is likely too small to provide any conclusive answer in terms of the impact of BPH surgery on EF outcomes. Therefore, while the current findings may be representative of this cohort of same-race heterosexual men, they certainly deserve external validation with a larger independent sample. Fourth, this particular study lacks the observation of both EF and ejaculatory/orgasmic outcomes at more points in time, data that would allow us to determine if the current findings are reliable and reproducible. Likewise, a penile doppler ultrasound assessment could have improved our findings to objectively interpreting erectile functioning both at baseline and over the FU period. Furthermore, our study lacks data on chronic medical therapy which could be potential predictors of changes in sexual functioning at long-term FU.

As a whole, these preliminary naturalistic data are useful for appropriately designing a longitudinal study whose findings would translate into knowledge that could be clinically applied to patient care and aid in decision making.

Our study confirmed that HoLEP for LUTS/BPH may be associated with a decrease in long-term postoperative EF at a long-term evaluation. Conversely, the current findings provide novel evidence showing that the severity of baseline LUTS and ED may account for a clinically meaningful improvement in long-term postoperative EF after HoLEP. Therefore, these results suggest that patients with severe LUTS, which could also negatively interfere with their sexual functioning, would probably benefit most from HoLEP in terms of clinically significant EF improvement, regardless of their age, even many years after BPH surgery. Additional prospective studies in larger population-based cohorts are certainly needed to confirm these results.

## CONFLICT OF INTEREST

The authors declare no conflict of interest.

## ACKNOWLEDGMENTS

We thank Dana Kuefner PhD for reviewing the language in this manuscript.

## REFERENCES

- 1 Gacci M, Eardley I, Giuliano F, Hatzichristou D, Kaplan SA, Maggi M *et al.* Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. *Eur Urol* 2011; **60**: 809–815.
- 2 Briganti A, Naspro R, Gallina A, Salonia A, Vavassori I, Hurler R *et al.* Impact on sexual function of Holmium laser enucleation versus transurethral resection of the prostate: results of a prospective, 2-center, randomized trial. *J Urol* 2006; **175**: 1817–1821.
- 3 Bruyère F, Puichaud A, Pereira H, Faivre d'Arcier B, Rouanet A, Floch AP *et al.* Influence of photoselective vaporization of the prostate on sexual function: results of a prospective analysis of 149 patients with long-term follow-up. *Eur Urol* 2010; **58**: 207–211.
- 4 Gillling PJ, Wilson LC, King CJ, Westenberg AM, Frampton CM, Fraundorfer MR. Long-term results of a randomized trial comparing holmium laser enucleation of the prostate and transurethral resection of the prostate: results at 7 years. *BJU Int* 2012; **109**: 408–411.
- 5 Jeong MS, Ha SB, Lee CJ, Cho MC, Kim SW, Paick JS. Serial changes in sexual function following holmium laser enucleation of the prostate: a short-term follow-up study. *Korean J Urol* 2012; **53**: 104–108.
- 6 Mamoulakis C, Skolarikos A, Schulze M, Scoffone CM, Rassweiler JJ, Alivizatos G *et al.* Bipolar vs monopolar transurethral resection of the prostate: evaluation of the impact on overall sexual function in an international randomized controlled trial setting. *BJU Int* 2013; **112**: 109–120.
- 7 Muntener M, Aellig S, Kuettel R, Gehrlach C, Sulser T, Strebler RT. Sexual function after transurethral resection of the prostate (TURP): results of an independent prospective multicentre assessment of outcome. *Eur Urol* 2007; **52**: 510–515.

- 8 Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC *et al*. European Association of Urology. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. *Eur Urol* 2013; **64**: 118–140.
- 9 Liefeldt HH, Stoevelaar HJ, McDonnell J. Sexual function before and after various treatments for symptomatic benign prostatic hyperplasia. *BJU Int* 2002; **89**: 208–213.
- 10 Zong HT, Peng XX, Yang CC, Zhang Y. The impact of transurethral procedures for benign prostatic hyperplasia on male sexual function: a meta-analysis. *J Androl* 2012; **33**: 427–434.
- 11 Elmansy HM, Kotb A, Elhilali MM. Holmium laser enucleation of the prostate: long-term durability of clinical outcomes and complication rates during 10 years of followup. *J Urol* 2011; **186**: 1972–1976.
- 12 Kuntz RM, Lehrich K, Ahyai SA. Holmium laser enucleation of the prostate versus open prostatectomy for prostates greater than 100 grams: 5-year follow-up results of a randomised clinical trial. *Eur Urol* 2008; **53**: 160–166.
- 13 Montorsi F, Naspro R, Salonia A, Suardi N, Briganti A, Zanon M *et al*. Holmium laser enucleation versus transurethral resection of the prostate: results from a 2-center prospective randomized trial in patients with obstructive benign prostatic hyperplasia. *J Urol* 2008; **179**: S87–S90.
- 14 Naspro R, Bachmann A, Gilling P, Kuntz R, Madersbacher S, Montorsi F *et al*. A review of the recent evidence (2006–2008) for 532-nm photoselective laser vaporisation and holmium laser enucleation of the prostate. *Eur Urol* 2009; **55**: 1345–1357.
- 15 Kuntz RM, Ahyai S, Lehrich K, Fayad A. Transurethral holmium laser enucleation of the prostate versus transurethral electrocautery resection of the prostate: a randomized prospective trial in 200 patients. *J Urol* 2004; **172**: 1012–1016.
- 16 Rosen RC, Allen KR, Ni X, Araujo AB. Minimal clinically important differences in the erectile function domain of the International Index of Erectile Function scale. *Eur Urol* 2011; **60**: 1010–1016.
- 17 Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis* 1987; **40**: 373–383.
- 18 Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. *Urology* 1997; **49**: 822–830.
- 19 Cappelleri JC, Rosen RC, Smith MD, Mishra A, Osterloh IH. Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. *Urology* 1999; **54**: 346–351.
- 20 Elshal AM, Elmansy HM, Elkoushy MA, Elhilali MM. Male sexual function outcome after three laser prostate surgical techniques: a single center perspective. *Urology* 2012; **80**: 1098–1104.
- 21 Gacci M, Bartoletti R, Figlioli S, Sarti E, Eisner B, Boddi V *et al*. Urinary symptoms, quality of life and sexual function in patients with benign prostatic hypertrophy before and after prostatectomy: a prospective study. *BJU Int* 2003; **91**: 196–200.
- 22 Martínez-Jabaloyas JM, Villamón-Fort R, Gil-Salom M, Gil-Salom M, Chuan-Nuez P. Impact of benign prostatic hyperplasia surgery on erectile function. *Urol Int* 2010; **84**: 407–412.
- 23 Mebust WK, Holtgrewe HL, Cockett AT, Peters PC. Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients. *J Urol* 1989; **141**: 243–247.
- 24 Madersbacher S, Marberger M. Is transurethral resection of the prostate still justified? *BJU Int* 1999; **83**: 227–237.
- 25 Choi SB, Zhao C, Park JK. The effect of transurethral resection of the prostate on erectile function in patients with benign prostatic hyperplasia. *Korean J Urol* 2010; **51**: 557–560.
- 26 Guo Z, Jin X. The volume of prostate can impact the male sexual function following photoselective vaporization of the prostate: results of a prospective analysis of 128 patients with 2-year follow-up. *Int Urol Nephrol* 2013; **45**: 961–966.
- 27 Meng F, Gao B, Fu Q, Chen J, Liu Y, Shi B *et al*. Change of sexual function in patients before and after Ho:YAG laser enucleation of the prostate. *J Androl* 2007; **28**: 259–261.
- 28 Kim SH, Yang HK, Lee HE, Paick JS, Oh SJ. HoLEP does not affect the overall sexual function of BPH patients: a prospective study. *Asian J Androl* 2014; **16**: 873–877.
- 29 Placer J, Salvador C, Planas J, Trilla E, Lorente D, Celma A *et al*. Effects of holmium laser enucleation of the prostate on sexual function. *J Endourol* 2015; **29**: 332–339.
- 30 Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E *et al*. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). *Eur Urol* 2003; **44**: 637–649.
- 31 Seftel AD, de la Rosette J, Birt J, Porter V, Zarotsky V, Viktrup L. Coexisting lower urinary tract symptoms and erectile dysfunction: a systematic review of epidemiological data. *Int J Clin Pract* 2013; **67**: 32–45.